Mammography and Beyond: Developing Technologies for the Early Detection of Breast Cancer (2001)

Page 249

Page 250

Anbar M, Brown CA, Milescu L, Babalola JA. Clinical Applications of DAT using a QWIP FPA camera. Infrared Technology and Applications XXV: April 5, 1999-April 9, 1999; Orlando, FL. Part of the SPIE Conference on Infared Technology and Applications XXV.

Anbar M, Brown C, Milescu L. Objective identification of cancerous breasts by dynamic area telethermometry (DAT). Thermology International. 1999; 127-33.

Anderson LF. Issues raised on availability of breast cancer materials for research [news]. J Natl Cancer Inst. 1994; 86: 1580-2.

Appleby JM, Barber JB, Levine E, et al. Absence of mutations in the ATM gene in breast cancer patients with severe responses to radiotherapy. Br J Cancer. 1997; 76: 1546-9.

Arfelli F, Assante M, Bonvicini V, et al. Low-dose phase contrast x-ray medical imaging. Phys Med Biol. 1998a; 43: 2845-52.

Arfelli F, Bonvicini V, Bravin A, et al. Mammography of a phantom and breast tissue with synchrotron radiation and a linear-array silicon detector. Radiology. 1998b; 208: 709-15.

Arfelli F, Bonvicini V, Bravin A, et al. Mammography with synchrotron radiation: phase-detection techniques. Radiology. 2000; 215: 286-93.

Aronowitz R. To screen or not to screen: What is the question? [editorial]. J Gen Intern Med. 1995; 10: 295-7.

Assurance Medical Inc. The Clinical Assessment of Electronic Palpation Technology: A New Approach for the Early Detection and Monitoring of Breast Lesions. 1999.

Aubry WM. Technology assessment and reimbursement for future new imaging technologies. Acad Radiol. 1998; 5 Suppl 2: S389-91.

Baines CJ. The Canadian National Breast Screening Study: a perspective on criticisms. Ann Intern Med. 1994; 120: 326-34.

Baines CJ, To T, Wall C. Women's attitudes to screening after participation in the National Breast Screening Study. A questionnaire survey. Cancer. 1990; 65: 1663-9.

Banta HD, Thacker SB. The case for reassessment of health care technology. Once is not enough [see comments]. JAMA. 1990; 264: 235-40.

Barton MB, Harris R, Fletcher SW. Does this patient have breast cancer? The screening clinical breast examination: should it be done? How? JAMA. 1999; 282: 1270-80.

Baylin SB, Herman JG, Graff JR, Vertino PM, Issa JP. Alterations in DNA methylation: a fundamental aspect of neoplasia. Adv Cancer Res. 1998; 72: 141-96.

Beam CA, Layde PM, Sullivan DC. Variability in the interpretation of screening mammograms by US radiologists. Findings from a national sample. Arch Intern Med. 1996; 156: 209-13.

Beam CA, Sullivan DC, Layde PM. Effect of human variability on independent double reading in screening mammography. Acad Radiol. 1996; 3: 891-7.

Bergstraesser LM, Weitzman SA. Culture of normal and malignant primary human mammary epithelial cells in a physiological manner simulates in vivo growth patterns and allows discrimination of cell type. Cancer Res. 1993; 53: 2644-54.

Berlin L. The missed breast cancer: perceptions and realities [see comments]. AJR Am J Roentgenol. 1999; 173: 1161-7.

Berry DA. Benefits and risks of screening mammography for women in their forties: a statistical appraisal [see comments]. J Natl Cancer Inst. 1998; 90: 1431-9.

Berx G, Becker KF, Hofler H, van Roy F. Mutations of the human E-cadherin (CDH1) gene. Hum Mutat. 1998; 12: 226-37.

Blackman DK, Bennett EM, Miller DS. Trends in self-reported use of mammograms (1989-1997) and Papanicolaou tests (1991-1997)—Behavioral Risk Factor Surveillance System. Mor Mortal Wkly Rep CDC Surveill Summ. 1999; 48: 1-22.

Blanks RG, Moss SM, McGahan CE, Quinn MJ, Babb PJ. Effect of NHS breast screening programme on mortality from breast cancer in England and Wales, 1990-8: comparison of observed with predicted mortality. BMJ. 2000; 321: 665-669.

Page 251

Blue Cross and Blue Shield Association Technology Evaluation Center AP. Scintimammography; 1997. Volume 12.

Bohorfoush AG. Tissue spectroscopy for gastrointestinal diseases. Endoscopy. 1996; 28: 372-80.

Bone B, Pentek Z, Perbeck L, Veress B. Diagnostic accuracy of mammography and contrast-enhanced MR imaging in 238 histologically verified breast lesions. Acta Radiol. 1997; 38: 489-96.

Borresen AL. Role of genetic factors in breast cancer susceptibility. Acta Oncol. 1992; 31: 151-5.

Bosanko CM, Baum JK, Clark K, Barth-Jones D, Levine AJ. Optical spectroscopy (INVOS) is unreliable in detecting breast cancer. Am J Roentgenol. 1990; 155: 43-7.

Bown SG, Bigio I, Briggs GM, Pickard CDO, Ripley P. Optical biopsy for the diagnosis of breast tumors. Era of Hope Department of Defense Breast Cancer Program Meeting: June, 2000.

Braslow NM, Shatin D, McCarthy DB, Newcomer LN. Role of technology assessment in health benefits coverage for medical devices. Am J Manag Care. 1998; 4 Spec No:SP139-50.

Braun S, Pantel K, Muller P, et al. Cytokeratin-positive cells in the bone marrow and survival of patients with stage I, II, or III breast cancer [see comments] [published erratum appears in N Engl J Med 2000 Jul 27;343(4): 308]. N Engl J Med. 2000; 342: 525-33.

Breast Cancer Progress Review Group. Charting The Course: Priorities For Breast Cancer Research: Breast Cancer Progress Review Group; 1998.

Brennan TA, Sox CM, Burstin HR. Relation between negligent adverse events and the outcomes of medical-malpractice litigation N Engl J Med. 1996; 335: 1963-7.

Brice J. Small change for big medicine: The crisis in breast imaging services. Diagn Imaging (San Franc). 2000; 22.

Bridges JE, inventor; Non-Invasive System for Breast Cancer Detection5704355. 1998 Jan 6.

Broeks A, Urbanus JH, Floore AN, et al. ATM-heterozygous germline mutations contribute to breast cancer-susceptibility. Am J Hum Genet. 2000; 66: 494-500.

Brown AD, Garber AM. Cost-effectiveness of 3 methods to enhance the sensitivity of Papanicolaou testing. JAMA. 1999; 281: 347-53.

Brown ML, Fintor L. Cost-effectiveness of breast cancer screening: preliminary results of a systematic review of the literature. Breast Cancer Res Treat. 1993; 25: 113-8.

Brown ML, Houn F, Sickles EA, Kessler LG. Screening mammography in community practice: positive predictive value of abnormal findings and yield of follow-up diagnostic procedures. AJR Am J Roentgenol. 1995; 165: 1373-7.

Burattini E, Cossu E, Di Maggio C, et al. Mammography with synchrotron radiation. Radiology. 1995; 195: 239-44.

Burke HB, Henson DE. Specimen banks for cancer prognostic factor research. Arch Pathol Lab Med. 1998; 122: 871-4.

Burke W, Daly M, Garber J, et al. Recommendations for follow-up care of individuals with an inherited predisposition to cancer. II. BRCA1 and BRCA2. Cancer Genetics Studies Consortium [see comments]. JAMA. 1997; 277: 997-1003.

Burman ML, Taplin SH, Herta DF, Elmore JG. Effect of false-positive mammograms on interval breast cancer screening in a health maintenance organization. Ann Intern Med. 1999; 131: 1-6.

Byng JW, Yaffe MJ, Jong RA, et al. Analysis of mammographic density and breast cancer risk from digitized mammograms. Radiographics. 1998; 18: 1587-98.

Canadian Association of Radiation Oncologists. The palpable breast lump: information and recommendations to assist decision-making when a breast lump is detected. The Steering Committee on Clinical Practice Guidelines for the Care and Treatment of Breast Cancer, [see comments]. CMAJ. 1998; 158 Suppl 3: S3-8.

Page 252

Carson PL, Fowlkes JB, Roubidoux MA, et al. 3-D color Doppler image quantification of breast masses. Ultrasound Med Biol. 1998; 24: 945-52.

Center for Disease Control and Prevention. Use of cervical and breast cancer screening among women with and without functional limitations—United States, 1994-1995. MMWR Morb Weekly Report. 1998; 47: 853-6.

Chan HP, Sahiner B, Helvie MA, et al. Improvement of radiologists' characterization of mammographic masses by using computer-aided diagnosis: an ROC study. Radiology. 1999; 212: 817-27.

Chance B. Near-infrared images using continuous, phase-modulated, and pulsed light with quantitation of blood and blood oxygenation. Ann N Y Acad Sci. 1998; 838: 29-45.

Chang CH, Sibala JL, Fritz SL, Dwyer SJ 3d, Templeton AW. Specific value of computed tomographic breast scanner (CT/M) in diagnosis of breast diseases. Radiology. 1979; 132: 647-52.

Chang CH, Sibala JL, Fritz SL, et al. Computed tomography in detection and diagnosis of breast cancer. Cancer. 1980; 46: 939-46.

Chang CH, Sibala JL, Gallagher JH, et al. Computed tomography of the breast. A preliminary report. Radiology. 1977; 124: 827-9.

Chaudhary SS, Mishra RK, Swarup A, Thomas JM. Dielectric properties of normal & malignant human breast tissues at radiowave & microwave frequencies. Indian J Biochem Biophys. 1984; 21: 76-9.

Chen J, Birkholtz GG, Lindblom P, Rubio C, Lindblom A. The role of ataxia-telangiectasia heterozygotes in familial breast cancer. Cancer Res. 1998; 58: 1376-9.

Cheung KL, Graves CR, Robertson JF. Tumour marker measurements in the diagnosis and monitoring of breast cancer. Cancer Treat Rev. 2000; 26: 91-102.

Christiansen CL, Wang F, Barton MB, et al. Predicting the cumulative risk of false-positive mammograms. J Natl Cancer Inst. 2000; 92: 1657-66.

Clarke C, Titley J, Davies S, O'Hare MJ. An immunomagnetic separation method using superparamagnetic (MACS) beads for large-scale purification of human mammary luminal and myoepithelial cells. Epithelial Cell Biol. 1994; 3: 38-46.

Clarke J. SQUIDS. Scientific American. 1994; 271: 46-53.

Clemons M, Loijens L, Goss P. Breast cancer risk following irradiation for Hodgkin's disease. Cancer Treat Rev. 2000; 26: 291-302.

Clontech Laboratories Inc. High Through Put Expression Profiling With Atlas; 1999.

Cocconi G. The natural history of operable breast cancer after primary treatment. Ann Oncol. 1995; 6 Suppl 2: 11-21.

Coleman EA. Practice and effectiveness of breast self examination: a selective review of the literature (1977-1989). J Cancer Educ. 1991; 6: 83-92.

Concato J, Shah N, Horwitz RI. Randomized, controlled trials, observational studies, and the hierarchy of research design. N Engl J Med. 2000; 342: 1887-92.

Connor F, Bertwistle D, Mee PJ, et al. Tumorigenesis and a DNA repair defect in mice with a truncating BRCA2 mutation. Nat Genet. 1997; 17: 423-30.

Cooper TA, Mattox W. The regulation of splice-site selection, and its role in human disease. Am J Hum Genet. 1997; 61: 259-66.

Cortez D, Wang Y, Qin J, Elledge SJ. Requirement of ATM-dependent phosphorylation of brcal in the DNA damage response to double-strand breaks. Science. 1999; 286: 1162-6.

Costello JF, Fruhwald MC, Smiraglia DJ, et al. Aberrant CpG-island methylation has non-random and tumour-type-specific patterns. Nat Genet. 2000; 24: 132-8.

Craft PS, Harris AL. Clinical prognostic significance of tumour angiogenesis. Ann Oncol. 1994; 5: 305-11.

Cutler M. Transillumination as an aid in the diagnosis of breast lesions. Surg Gynecol Obstet. 1929; 48: 721-9.

Page 253

Cuzick J, Holland R, Barth V, et al. Electropotential measurements as a new diagnostic modality for breast cancer. Lancet. 1998; 352: 359-63.

Daly MB, Offit K, Li F, et al. Participation in the cooperative family registry for breast cancer studies: issues of informed consent. J Natl Cancer Inst. 2000; 92: 452-6.

Dawson PJ, Wolman SR, Tait L, Heppner GH, Miller FR. MCF10AT: a model for the evolution of cancer from proliferative breast disease. Am J Pathol. 1996; 148: 313-9.

DeBruhl ND, Bassett LW, Jessop NW, Mason AM. Mobile mammography: results of a national survey. Radiology. 1996; 201: 433-7.

Del Vecchio S, Ciarmiello A, Salvatore M. Clinical imaging of multidrug resistance in cancer. Q J Nucl Med. 1999; 43: 125-31.

Department of Labor et al., Genetic Information and the Workplace: (January 20, 1998).

Detsky AS, Naglie IG. A clinician's guide to cost-effectiveness analysis. Ann Intern Med. 1990; 113: 147-54.

Doi K, Giger ML, Nishikawa RM, Schmidt RA. Computer-Aided Diagnosis of Breast Cancer on Mammograms. Breast Cancer. 1997; 4: 228-233.

Doyle AJ, Murray KA, Nelson EW, Bragg DG. Selective use of image-guided large-core needle biopsy of the breast: accuracy and cost-effectiveness. Am J Roentgenol. 1995; 165: 281-4.

Duijm LE, Guit GL, Zaat JO, Koomen AR, Willebrand D. Sensitivity, specificity and predictive values of breast imaging in the detection of cancer. Br J Cancer. 1997; 76: 377-81.

Dunning AM, Healey CS, Pharoah PD, Teare MD, Ponder BA, Easton DF. A systematic review of genetic polymorphisms and breast cancer risk. Cancer Epidemiol Biomarkers Prev. 1999; 8: 843-54.

Eastern Research Group. Cost and Benefit Analysis of Regulation Under the Mammograpgy Quality Standards Act of 1992 Preliminary Report; 1996.

Easton DF, Bishop DT, Ford D, Crockford GP. Genetic linkage analysis in familial breast and ovarian cancer: results from 214 families. The Breast Cancer Linkage Consortium. Am J Hum Genet. 1993; 52: 678-701.

Edell SL, Eisen MD. Current imaging modalities for the diagnosis of breast cancer. Del Med J. 1999; 71: 377-82.

Eisen A, Rebbeck TR, Wood WC, Weber BL. Prophylactic surgery in women with a hereditary predisposition to breast and ovarian cancer. J Clin Oncol. 2000; 18: 1980-95.

Eisen MB, Spellman PT, Brown PO, Botstein D. Cluster analysis and display of genomewide expression patterns. Proc Natl Acad Sci U S A. 1998; 95: 14863-8.

Eisenberg JM. Ten lessons for evidence-based technology assessment. JAMA. 1999; 282: 1865-9.

Eklund GW. Shortage of qualified breast imagers could lead to crisis. Diagn Imaging (San Franc). 2000; 22(4): 31-3, 69.

Elmore JG, Barton MB, Moceri VM, Polk S, Arena PJ, Fletcher SW. Ten-year risk of false positive screening mammograms and clinical breast examinations. N Engl J Med. 1998a; 338: 1089-96.

Elmore JG, Wells CK, Howard DH. Does diagnostic accuracy in mammography depend on radiologists' experience? J Womens Health. 1998b; 7: 443-9.

Elmore JG, Wells CK, Lee CH, Howard DH, Feinstein AR. Variability in radiologists' interpretations of mammograms. N Engl J Med. 1994; 331: 1493-9.

Emmert-Buck MR, Bonner RF, Smith PD, et al. Laser capture microdissection. Science. 1996; 274: 998-1001.

Engel LW, Young NA. Human breast carcinoma cells in continuous culture: a review. Cancer Res. 1978; 38: 4327-39.

Ernster VL, Barclay J. Increases in ductal carcinoma in situ (DCIS) of the breast in relation to mammography: a dilemma. J Natl Cancer Inst Monogr. 1997: 151-6.

Page 254

Ernster VL, Barclay J, Kerlikowske K, Grady D, Henderson C. Incidence of and treatment for ductal carcinoma in situ of the breast. JAMA. 1996; 275: 913-8.

Fabian C., O'Shaughnessy J., Mayo M.S., et al. Prevention Clinical Trial Models Utilizing Breast Intraepitheial Neoplasia as an Endpoint. In press.

Fajardo LL, DeAngelis GA. The role of stereotactic biopsy in abnormal mammograms. Surg Oncol Clin N Am. 1997; 6: 285-99.

Farria DM, Debruhl N, Gorczyca D, Bassett LW. Magnetic Resonance Imaging of Breast Tumors. Seminars In Breast Disease. 1999; 2: 74-88.

Farria D, Feig SA. An introduction to economic issues in breast imaging. Radiol Clin North Am. 2000; 38: 825-42.

Faupel M, Vanel D, Barth V, et al. Electropotential evaluation as a new technique for diagnosing breast lesions. Eur J Radiol. 1997; 24: 33-8.

Fear EC, Stuchly MA. Microwave System for Breast Tumor Detection. IEEE Microwave and Guided Wave Letters. 1999; 9: 470-2.

Federal Register. Medicare Program: Procedures for Making National Coverage Decisions. 1999; 64(80): 22619-25.

Federal Register. Medicare Program: Criteria for Making Coverage Decisions. 2000; 65(95): 31124-29.

Feig. SBI News, President's Message: Behind the Scenes of an SBI Epic Production; 2000a.

Feig S. Principles and practice of breast imaging, Seminars in breast disease. 1999a; 2: 3-16.

Feig SA. Economic challenges in breast imaging. A survivor's guide to success. Radiol Clin North Am. 2000b; 38: 843-52.

Feig SA. President's Message: SBI Residency Training Curriculum; 1999b.

Feig SA. Role and evaluation of mammography and other imaging methods for breast cancer detection, diagnosis, and staging. Semin Nucl Med. 1999c; 29: 3-15.

Feig SA, Hendrick RE. Radiation risk from screening mammography of women aged 40-49 years. J Natl Cancer Inst Monogr. 1997: 119-24.

Feig SA, Shaber GS, Schwartz GF, et al. Thermography, mammography, and clinical examination in breast cancer screening. Review of 16,000 studies. Radiology. 1977; 122: 123-7.

Fisher B, Costantino JP, Wickerham DL, et al. Tamoxifen for prevention of breast cancer: report of the National Surgical Adjuvant Breast and Bowel Project P-1 Study. J Natl Cancer Inst. 1998a; 90: 1371-88.

Fisher B, Dignam J, Wolmark N, et al. Lumpectomy and radiation therapy for the treatment of intraductal breast cancer: findings from National Surgical Adjuvant Breast and Bowel Project B-17. J Clin Oncol. 1998b; 16: 441-52.

FitzGerald MG, Bean JM, Hegde SR, et al. Heterozygous ATM mutations do not contribute to early onset of breast cancer. Nat Genet. 1997; 15: 307-10.

Fitzgibbons PL, Page DL, Weaver D, et al. Prognostic factors in breast cancer. College of American Pathologists Consensus Statement 1999. Arch Pathol Lab Med. 2000; 124: 966-78.

Fletcher RH., Fletcher SW, Wagner EH. Clinical Epidemiology - the Essentials. 3rd Ed. Baltimore, MD: Williams & Wilkins; 1996.

Fliss MS, Usadel H, Caballero OL, et al. Facile detection of mitochondrial DNA mutations in tumors and bodily fluids. Science. 2000; 287: 2017-9.

Foray N, Randrianarison V, Marot D, Perricaudet M, Lenoir G, Feunteun J. Gamma-rays-induced death of human cells carrying mutations of BRCA1 or BRCA2. Oncogene. 1999; 18: 7334-42.

Ford D, Easton DF, Bishop DT, Narod SA, Goldgar DE. Risks of cancer in BRCA1-mutation carriers. Breast Cancer Linkage Consortium. Lancet. 1994; 343: 692-5.

Foster KR. Thermographic detection of breast cancer [see comments]. IEEE Eng Med Biol Mag 1998; 17: 10-4.

Page 255

Fox SA, Stein JA. The effect of physician-patient communication on mammography utilization by different ethnic groups. Med Care. 1991; 29: 1065-82.

Fuchs VR. Health care for the elderly: how much? Who will pay for it? Health Aff (Millwood). 1999; 18: 11-21.

Fukuda M, Shimizu K, Okamoto N, et al. Prospective evaluation of skin surface electro-potentials in Japanese patients with suspicious breast lesions. Jpn J Cancer Res. 1996; 87: 1092-6.

Fuller BP, Kahn MJ, Barr PA, et al. Privacy in genetics research. Science. 1999; 285: 1359-61.

Gail M, Rimer B. Risk-based recommendations for mammographic screening for women in their forties [see comments] [published erratum appears in J Clin Oncol 1999 Feb; 17(2): 740]. J Clin Oncol. 1998; 16: 3105-14.

Gelijns and Rosenberg Diagnostic Devices. The Sources of Industrial Leadership, Edited by David Mowery and Richard Nelson. Cambridge; 1999.

Glasspool RM, Evans TR. Clinical imaging of cancer metastasis. Eur J Cancer. 2000; 36: 1661-70.

Gold MR, Siegel JE, Russell LB, Weinstein MC. Cost-Effectiveness in Health and Medicine. New York: Oxford University Press; 1996.

Gold RH, Bassett LW, Widoff BE. Highlights from the history of mammography. Radiographics. 1990; 10: 1111-31.

Goldenberg DM, Nabi HA. Breast cancer imaging with radiolabeled antibodies. Semin Nucl Med. 1999; 29: 41-8.

Golub G. Heroic Myths and Probability: Confronting the Limits of Screening. From: Kramer, BS; Gohagan, JK; Prorok, PC Cancer Screening: Theory and Practice. New York: M. Dekker; 1999: 13-26.

Goodman CJ, Lindsey JI, Whigham CJ, Robinson A. Diagnostic radiology residents in the classes of 1999 and 2000: fellowship and employment. AJR Am J Roentgenol. 2000; 174: 1211-3.

Goodman CS. Healthcare technology assessment: methods, framework, and role in policy making. Am J Manag Care . 1998; 4 Spec No:SP200-14; quiz SP215-6.

Gotzsche PC, Olsen O. Is screening for breast cancer with mammography justifiable? Lancet. 2000; 355: 129-34.

Grady KE, Lemkau JP, McVay JM, Reisine ST. The importance of physician encouragement in breast cancer screening of older women. Prev Med. 1992; 21: 766-80.

Graham-Rowe D. Closing in on cancer. New Scientist. 1999.

Gram IT, Lund E, Slenker SE. Quality of life following a false positive mammogram. Br J Cancer. 1990; 62: 1018-22.

Gribbestad IS, Singstad TE, Nilsen G, et al. In vivo 1H MRS of normal breast and breast tumors using a dedicated double breast coil. J Magn Reson Imaging. 1998; 8: 1191-7.

Gribbestad IS, Sitter B, Lundgren S, Krane J, Axelson D. Metabolite composition in breast tumors examined by proton nuclear magnetic resonance spectroscopy. Anticancer Res. 1999; 19: 1737-46.

Grizzle WE, Aamodt R, Clausen K, LiVolsi V, Pretlow TG, Qualman S. Providing human tissues for research: how to establish a program. Arch Pathol Lab Med. 1998; 122: 1065-76.

Hacia JG, Brody LC, Chee MS, Fodor SP, Collins FS. Detection of heterozygous mutations in BRCA1 using high density oligonucleotide arrays and two-colour fluorescence analysis [see comments]. Nat Genet. 1996; 14: 441-7.

Hacia JG, Collins FS. Mutational analysis using oligonucleotide microarrays. J Med Genet. 1999; 36: 730-6.

Hagness SC, Taflove A, Bridges JE. Two-dimensional FDTD analysis of a pulsed microwave confocal system for breast cancer detection: fixed-focus and antenna-array sensors [published erratum appears in IEEE Trans Biomed Eng 1999 Mar; 46(3): 364]. IEEE Trans Biomed Eng. 1998; 45: 1470-9.

Page 256

Hakama M, Pukkala E, Heikkila M, Kallio M. Effectiveness of the public health policy for breast cancer screening in Finland: population based cohort study. BMJ. 1997; 314: 864-7.

Haley S. Bill to create bioimaging, bioengineering institute at NIH clears House. Advocates hope for pre-recess vote on Lott-sponsored Senate companion bill. Washington Fax. 2000.

Hall HG, Farson DA, Bissell MJ. Lumen formation by epithelial cell lines in response to collagen overlay: a morphogenetic model in culture. Proc Natl Acad Sci U S A. 1982; 79: 4672-6.

Hancock SL, Cox RS, McDougall IR. Thyroid diseases after treatment of Hodgkin's disease. N Engl J Med. 1991; 325: 599-605.

Hankinson SE, Willett WC, Colditz GA, et al. Circulating concentrations of insulin-like growth factor-I and risk of breast cancer. Lancet. 1998; 351: 1393-6.

Haran C. Services denied: why women with disabilities aren't screened for cancer. MAMM. 2000 ;3.

Harris EL. Genetic inheritance of cancer risk: applications to cancer screening. From: Kramer BS, Gohagan JK, Prorok PC, eds. Cancer Screening: Theory and Practice. New York: M. Dekker; 1999: 595-609.

Harris R. Decision-making about screening: individual and policy levels. From: Kramer BS, Gohagan JK, Prorok PC, eds. Cancer Screening: Theory and Practice. New York: M. Dekker; 1999: 55-75.

Hartmann LC, Schaid D, Sellers T, et al. Bilateral Prophylactic Mastectomy (PM) in BRCA1/ 2 Mutation Carriers. Proceedings of the Annual Meeting of the American Association for Cancer Research: 2000.

Harvey JA, Fajardo LL, Innis CA. Previous mammograms in patients with impalpable breast carcinoma: retrospective vs blinded interpretation. 1993 ARRS President's Award [see comments]. AJR Am J Roentgenol. 1993; 161: 1167-72.

Havighurst CC. Health care law and policy: readings, notes and questions. 1998. Edited by: Clark C. Havighurst, James F. Blumstein and Troyen A. Brennan. 2nd Edition. New York: Foundation Press, 1998.

Hayes DF, Bast RC, Desch CE, et al. Tumor marker utility grading system: a framework to evaluate clinical utility of tumor markers [see comments]. J Natl Cancer Inst. 1996; 88: 1456-66.

Hayes DF, Trock B, Harris AL. Assessing the clinical impact of prognostic factors: when is “statistically significant” clinically useful? Breast Cancer Res Treat. 1998; 52: 305-19.

Head JF, Elliott RL. Thermography. Its relation to pathologic characteristics, vascularity, proliferation rate, and survival of patients with invasive ductal carcinoma of the breast [letter; comment]. Cancer. 1997; 79: 186-8.

Health and Human Services. Investigational Device Exemptions Manual; 1996. HHS Publication FDA 96-4159.

Health Care Financing Administration/Food and Drug Administration. Interagency Agreement Between the Food and Drug Administration and the Health Care Financing Administration Regarding Medicare Coverage of Certain Investigational Medical Devices (IDE Memorandum D95-2). 1995.

Hebden JC, Delpy DT. Diagnostic imaging with light. Br J Radiol. 1997; 70 Spec No:S206-14.

Heimann R, Bradley J, Hellman S. The benefits of mammography are not limited to women of ages older than 50 years [see comments]. Cancer. 1998; 82: 2221-6.

Heimann R, Hellman S. Individual characterisation of the metastatic capacity of human breast carcinoma. Eur J Cancer. 2000; 36: 1631-9.

Henschke CI, McCauley DI, Yankelevitz DF, et al. Early Lung Cancer Action Project: overall design and findings from baseline screening [see comments]. Lancet. 1999; 354: 99-105.

Page 257

Heppner GH, Wolman SR, Rosen J, Salomon D, Smith G, Mohla S. Research potential of a unique xenograft model of human proliferative breast disease. Breast Cancer Res Treat. 1999; 58: 183-6.

Hetelekidis S, Collins L, Silver B, et al. Predictors of local recurrence following excision alone for ductal carcinoma in situ. Cancer. 1999; 85: 427-31.

Hillner BE, Bear HD, Fajardo LL. Estimating the cost-effectiveness of stereotaxic biopsy for nonpalpable breast abnormalities: a decision analysis model. Acad Radiol. 1996; 3: 351-60.

Hoffman C. Uninsured in America: A Chart Book. The Kasier Commission on Medicaid and the Uninsured. 1998.

Hoffman JM, Menkens AE. Molecular imaging in cancer: future directions and goals of the National Cancer Institute. Acad Radiol. 2000; 7: 905-7.

Holtzman NA. Are genetic tests adequately regulated? [editorial]. Science. 1999; 286: 409.

Houn F, Bright RA, Bushar HF, et al. Study design in the evaluation of breast cancer imaging technologies. Acad Radiol. 2000; 7: 684-92.

Hrung JM, Langlotz CP, Orel SG, Fox KR, Schnall MD, Schwartz JS. Cost-effectiveness of MR imaging and core-needle biopsy in the preoperative work-up of suspicious breast lesions. Radiology. 1999; 213: 39-49.

Hrung JM, Sonnad SS, Schwartz JS, Langlotz CP. Accuracy of MR imaging in the work-up of suspicious breast lesions: a diagnostic meta-analysis. Acad Radiol. 1999; 6: 387-97.

Hutchinson ML, Berger BM, Farber FL. Clinical and cost implications of new technologies for cervical cancer screening: the impact of test sensitivity. Am J Managed Care. 2000; 6: 766-80.

Inman M. The negative impact of MQSA (Mammography Quality Standards Act) on rural mammography programs. Radiol Manage. 1998; 20: 31-9.

Institute of Medicine. Ensuring Quality Cancer Care. M Hewitt and JV Simone, editors. Washington, D.C.: National Academy Press; 1999.

Institute of Medicine. Extending Medicare Reimbursement in Clinical Trials. Aaron HJ, Gelband H., editors. Washington, D.C.: National Academy Press; 2000.

Institute of Medicine. Mathematics and Physics of Emerging Biomedical Imaging. Washington, D.C.: National Academy Press; 1996.

Institute of Medicine. A Review of the Department of Defense's Program for Breast Cancer Research. Washington, D.C.: National Academy Press; 1997.

Institute of Medicine. Strategies for Managing the Breast Cancer Research Program: A Report to the U.S. Army Medical Research and Development Command. Washington, D.C.: National Academy Press; 1993.

Izatt L, Greenman J, Hodgson S, et al. Identification of germline missense mutations and rare allelic variants in the ATM gene in early-onset breast cancer. Genes Chromosomes Cancer. 1999; 26: 286-94.

Jatoi I. Breast cancer screening. Am J Surg. 1999; 177: 518-24.

Joines WT, Jirtle RL, Rafal MD, Schaefer DJ. Microwave power absorption differences between normal and malignant tissue. Int J Radiat Oncol Biol Phys. 1980; 6: 681-7.

Joines WT, Zhang Y, Li C, Jirtle RL. The measured electrical properties of normal and malignant human tissues from 50 to 900 MHz. Med Phys. 1994; 21: 547-50.

Jones BF. A reappraisal of the use of infrared thermal image analysis in medicine. IEEE Trans Med Imaging . 1998; 17: 1019-27.

Kahan J.S. The Framework for Regulation of Medical Devices. Medical Devices, Obtaining FDA Market Clearence. 1995. PARAXEL International Corporation, Waltham, MA.

Katz SJ, Hofer TP. Socioeconomic disparities in preventive care persist despite universal coverage. Breast and cervical cancer screening in Ontario and the United States. JAMA. 1994; 272: 530-4.

Page 258

Kerlikowske K. Efficacy of screening mammography among women aged 40 to 49 years and 50 to 69 years: comparison of relative and absolute benefit. J Natl Cancer Inst Monogr. 1997: 79-86.

Kerlikowske K, Grady D, Barclay J, Sickles EA, Eaton A, Ernster V. Positive predictive value of screening mammography by age and family history of breast cancer. JAMA. 1993; 270: 2444-50.

Kerlikowske K, Grady D, Barclay J, Sickles EA, Ernster V. Likelihood ratios for modern screening mammography. Risk of breast cancer based on age and mammographic interpretation. JAMA. 1996; 276: 39-43.

Kerlikowske K, Grady D, Rubin SM, Sandrock C, Ernster VL. Efficacy of screening mammography. A meta-analysis. JAMA. 1995; 273: 149-54.

Kerlikowske K, Salzmann P, Phillips KA, Cauley JA, Cummings SR. Continuing screening mammography in women aged 70 to 79 years: impact on life expectancy and cost-effectiveness. JAMA. 1999; 282: 2156-63.

Kevles B. Naked to the Bone: Medical Imaging in the Twentieth Century. New Brunswick, NJ: Rutgers University Press; 1997.

Khalkhali I, Mena I, Jouanne E, et al. Prone scintimammography in patients with suspicion of carcinoma of the breast. J Am Coll Surg. 1994; 178: 491-7.

Kinoshita J, Haga S, Shimizu T, Imamura H, Watanabe O, Kajiwara T. The expression of variant exon v7-v8 CD44 antigen in relation to lymphatic metastasis of human breast cancer. Breast Cancer Res Treat. 1999; 53: 177-83.

Kleiner K. More gain, less pain. New Scientist. 1999.

Knopp MV, Weiss E, Sinn HP, et al. Pathophysiologic basis of contrast enhancement in breast tumors. J Magn Reson Imaging. 1999; 10: 260-6.

Koenig BA, Greely HT, McConnell LM, Silverberg HL, Raffin TA. Genetic testing for BRCA1 and BRCA2: recommendations of the Stanford Program in Genomics, Ethics, and Society. Breast Cancer Working Group. J Womens Health. 1998; 7: 531-45.

Kolb GR. Multidisciplinary breast cancer survival, part I and II. ADVANCE for Administrators in Radiology and Radiation Oncology. 2000.

Kolb TM, Lichy J, Newhouse JH. Occult cancer in women with dense breasts: detection with screening US—diagnostic yield and tumor characteristics. Radiology. 1998; 207: 191-9.

Kononen J, Bubendorf L, Kallioniemi A, et al. Tissue microarrays for high-throughput molecular profiling of tumor specimens. Nat Med. 1998; 4: 844-7.

Kopans DB. The positive predictive value of mammography. Am J Roentgenol. 1992; 158: 521-6.

Kopans DB, Moore RH, McCarthy KA, et al. Positive predictive value of breast biopsy performed as a result of mammography: there is no abrupt change at age 50 years. Radiology. 1996; 200: 357-60.

Kruger DG, Abreu CC, Hendee EG, et al. Imaging characteristics of x-ray capillary optics in digital mammography. Med Phys. 1996; 23: 187-96.

Kruger RA, inventor; Photoacoustic Breast Scanner 5713356. 1998 Feb 3.

Kruger RA, Kiser Jr WL, Reinecke DR, Kruger GA. Application of thermoacoustic computed tomography to breast imaging. SPIE. 1999; 3659: 426-30.

Kruger RA, Kopecky KK, Aisen AM, Reinecke DR, Kruger GA, Kiser WL Jr. Thermoacoustic CT with radio waves: a medical imaging paradigm. Radiology. 1999; 211: 275-8.

Kuhl CK, Schmutzler RK, Leutner CC, et al. Breast MR imaging screening in 192 women proved or suspected to be carriers of a breast cancer susceptibility gene: preliminary results. Radiology. 2000; 215: 267-79.

Kvistad KA, Bakken IJ, Gribbestad IS, et al. Characterization of neoplastic and normal human breast tissues with in vivo (1)H MR spectroscopy. J Magn Reson Imaging. 1999; 10: 159-64.

Page 259

Lakin ND, Jackson SP. Regulation of p53 in response to DNA damage. Oncogene. 1999; 18: 7644-55.

Land CE. Estimating cancer risks from low doses of ionizing radiation. Science. 1980; 209: 1197-203.

Lane DS, Caplan LS, Grimson R. Trends in mammography use and their relation to physician and other factors. Cancer Detect Prev. 1996; 20: 332-41.

Larsen LE, Jacobi JH, Eds. Medical Applications of Microwave Imaging. Piscataway, NJ: IEEE Press; 1986.

Lawrence WF, Liang W, Mandelblatt JS, et al. Serendipity in diagnostic imaging: magnetic resonance imaging of the breast. J Natl Cancer Inst. 1998; 90: 1792-800.

Lawson RN. Implications of surface temperatures in the diagnosis of breast cancer. Can. Med. Assoc. J. 1956; 75: 309-10.

Laya MB, Larson EB, Taplin SH, White E. Effect of estrogen replacement therapy on the specificity and sensitivity of screening mammography. J Natl Cancer Inst. 1996; 88: 643-9.

Lerman C, Trock B, Rimer BK, Jepson C, Brody D, Boyce A. Psychological side effects of breast cancer screening. Health Psychol. 1991; 10: 259-67.

Lerner B.H. To See Today With the Eyes of Tomorrow: A History of Screening Mammography. 2001. (see http://www4.nationalacademies.org/IOM/IOMHome.nsf/Pages/Breast+Cancer+Detection)

Lewin JM. Full-field digital mammography. A candid assessment. Diagn Imaging (San Franc). 1999; 21: 40-5.

Lewin JM, Hendrick RE, D'Orsi CJ, Isaacs PK, Moss LJ, Karellas A, Sisney GA, Kuni CC, Cutter GR. Comparison of full-field digital mammography with screen-film mammography for cancer detection: results of 4945 paired examinations. Radiology 2001; 218: 873-80.

Lewin J, Hendrick RE, D'Orsi CJ, Moss LJ, Isaacs P. Clinical Evaluation of Full-Field Digital Mammography in a Screening Population. 2000 Annual Meeting of the Radiological Society of North America.

Li S, Ting NS, Zheng L, et al. Functional link of BRCA1 and ataxia telangiectasia gene product in DNA damage response. Nature. 2000; 406: 210-5.

Liaw D, Marsh DJ, Li J, et al. Germline mutations of the PTEN gene in Cowden disease, an inherited breast and thyroid cancer syndrome. Nat Genet. 1997; 16: 64-7.

Lichtenstein P, Holm NV, Verkasalo PK, et al. Environmental and heritable factors in the causation of cancer—analyses of cohorts of twins from Sweden, Denmark, and Finland. N Engl J Med. 2000; 343: 78-85.

Lidbrink E, Elfving J, Frisell J, Jonsson E. Neglected aspects of false positive findings of mammography in breast cancer screening: analysis of false positive cases from the Stockholm trial. BMJ. 1996; 312: 273-6.

Lijmer JG, Mol BW, Heisterkamp S, et al. Empirical evidence of design-related bias in studies of diagnostic tests [published erratum appears in JAMA 2000 Apr 19;283(15): 1963]. JAMA. 1999; 282: 1061-6.

Liotta LA, Petricoin EF. Beyond the genome to tissue proteomics. Breast Cancer Research. 2000; 2: 13-14.

Louie AY, Huber MM, Ahrens ET, et al. In vivo visualization of gene expression using magnetic resonance imaging. Nat Biotechnol. 2000; 18: 321-5.

Love SM, Barsky SH. Breast-duct endoscopy to study stages of cancerous breast disease. Lancet. 1996; 348: 997-9.

Love SM, Chou J, Offodile R, et al. Development of Intraductal Techniques for Breast Cancer Prevention, Diagnosis and Treatment. Proceedings, Era of Hope Dept. of Defense Breast Cancer Research Program Meeting. 2000 June.

Love SM, Lindsey K. Dr. Susan Love's Breast Book. Reading, PA: Addison-Wesley; 1995.

Page 260

Lowe JB, Balanda KP, Del Mar C, Hawes E. Psychologic distress in women with abnormal findings in mass mammography screening. Cancer. 1999; 85: 1114-8.

Lu YJ, Osin P, Lakhani SR, Di Palma S, Gusterson BA, Shipley JM. Comparative genomic hybridization analysis of lobular carcinoma in situ and atypical lobular hyperplasia and potential roles for gains and losses of genetic material in breast neoplasia. Cancer Res. 1998; 58: 4721-7.

MacBeath G, Schreiber SL. Printing proteins as microarrays for high-throughput function determination. Science. 2000; 289: 1760-3.

Mackinnon WB, Barry PA, Malycha PL, et al. Fine-needle biopsy specimens of benign breast lesions distinguished from invasive cancer ex vivo with proton MR spectroscopy. Radiology. 1997; 204: 661-6.

Mahmood U, Tung CH, Bogdanov A Jr, Weissleder R. Near-infrared optical imaging of protease activity for tumor detection. Radiology. 1999; 213: 866-70.

Makuc DM, Breen N, Freid V. Low income, race, and the use of mammography. Health Serv Res. 1999; 34: 229-39.

Malkin D, Li FP, Strong LC, et al. Germ line p53 mutations in a familial syndrome of breast cancer, sarcomas, and other neoplasms. Science. 1990; 250: 1233-8.

Mandelblatt JS, Gold K, O'Malley AS, et al. Breast and cervix cancer screening among multiethnic women: role of age, health, and source of care. Prev Med. 1999; 28: 418-25.

Mandelblatt JS, Yabroff KR. Effectiveness of interventions designed to increase mammography use: a meta-analysis of provider-targeted strategies. Cancer Epidemiol Biomarkers Prev. 1999; 8: 759-67.

Mandelblatt J, Andrews H, Kao R, Wallace R, Kerner J. Impact of access and social context on breast cancer stage at diagnosis. J Health Care Poor Underserved. 1995; 6: 342-51.

Mandelson MT, Oestreicher N, Porter PL, et al. Breast density as a predictor of mammographic detection: comparison of interval- and screen-detected cancers. J Natl Cancer Inst. 2000; 92: 1081-7.

Mandelson MT, Wagner EH, Thompson RS. PSA screening: a public health dilemma. Annu Rev Public Health. 1995; 16: 283-306.

Mark HF, Jenkins R, Miller WA. Current applications of molecular cytogenetic technologies. Ann Clin Lab Sci. 1997; 27: 47-56.

Marshall E. The politics of breast cancer [news]. Science. 1993; 259: 616-7.

Martin S, Jansen F, Bokelmann J, Kolb H. Soluble CD44 splice variants in metastasizing human breast cancer. Int J Cancer. 1997; 74: 443-5.

Martinez B. Screening Crunch—As more women seek mammograms, many have to wait months. Wall Street Journal. 2000.

Matsumura Y, Tarin D. Significance of CD44 gene products for cancer diagnosis and disease evaluation. Lancet. 1992; 340: 1053-8.

May DS, Kiefe CI, Funkhouser E, Fouad MN. Compliance with mammography guidelines: physician recommendation and patient adherence. Prev Med. 1999; 28: 386-94.

Meaney PM, Paulsen KD, Chang JT, Fanning MW, Hartov A. Nonactive antenna compensation for fixed-array microwave imaging: Part II—Imaging results. IEEE Trans Med Imaging. 1999; 18: 508-18.

Medical Technology Leadership Forum. MTLF Summit: Conditional Coverage of Investigational Technologies. Bethesda, MD: Medical Technology Leadership Forum; 1999.

Mehta TS, Raza S, Baum JK. Use of Doppler ultrasound in the evaluation of breast carcinoma. Semin Ultrasound CT MR. 2000; 21: 297-307.

Merchant TE. MR spectroscopy of the breast. Magn Reson Imaging Clin N Am. 1994; 2: 691-703.

Merritt CRB. Future directions in breast ultrasonography. Seminars in Breast Disease. 1999; 2: 89-96.

Mettlin C. Global breast cancer mortality statistics. CA Cancer J Clin. 1999; 49: 138-44.

Page 261

Meyer JE, Smith DN, DiPiro PJ, et al. Stereotactic breast biopsy of clustered microcalcifications with a directional, vacuum-assisted device. Radiology. 1997; 204: 575-6.

Miki Y, Swensen J, Shattuck-Eidens D, et al. A strong candidate for the breast and ovarian cancer susceptibility gene BRCA1. Science. 1994; 266: 66-71.

Milbank Memorial Fund. Better Information, Better Outcomes? The Use of Health Technology Assessment and Clinical Effectiveness Data in the United Kingdom and the United States; 2000.

Miller AB, Baines CJ, To T, Wall C. Canadian National Breast Screening Study: 2. Breast cancer detection and death rates among women aged 50 to 59 years [published erratum appears in Can Med Assoc J 1993 Mar 1;148(5): 718]. CMAJ. 1992; 147: 1477-88.

Miller AB, To T, Baines CJ, Wall C. Canadian National Breast Screening Study-2: 13-Year Results of a Randomized Trial in Women Aged 50-59 Years. J Natl Cancer Inst. 2000; 92: 1490-1499.

Mittra I, Baum M, Thornton H, Houghton J. Is clinical breast examination an acceptable alternative to mammographic screening? BMJ. 2000; 321: 1071-1073.

Monaghan P, Clarke CL, Perusinghe NP, Ormerod MG, O'Hare MJ. Epidermal growth factor receptor expression on human breast luminal and basal cells in vitro. Epithelial Cell Biol. 1995; 4: 52-62.

Morrow M. When can stereotactic core biopsy replace excisional biopsy?—A clinical perspective. Breast Cancer Res Treat. 1995; 36: 1-9.

Moskowitz M. Thermography as a risk indicator of breast cancer. Results of a study and a review of the recent literature. J Reprod Med. 1985; 30: 451-9.

Moskowitz M, D'Orsi CJ, Bartrum RJ, Swets J. Breast Cancer Diagnosis by Lightscan (Revised) Final Report: National Cancer Institute; 1989. Grant Number CA37970.

Moss MS. Breast cancer. In: Kramer BS, Gohagan JK, Prorok PC, eds. Cancer Screening: Theory and Practice. New York: M. Dekker; 1999: 143-170.

Mountford C, Somorjai R, Gluch L, et al. Magnetic Resonance Spectroscopy Determines Pathology, Vascularisation and Node Status. Era of Hope. Department of Defense Breast Cancer Research Program Meeting: June, 2000; Atlanta, GA.

Mourant JR, Bigio IJ, Boyer J, Conn RL, Johnson T, Shimada T. Spectroscopic diagnosis of bladder cancer with elastic light scattering. Lasers Surg Med. 1995; 17: 350-7.

Mushlin AI, Kouides RW, Shapiro DE. Estimating the accuracy of screening mammography: a meta-analysis. Am J Prev Med. 1998; 14: 143-53.

Muthupillai R, Lomas DJ, Rossman PJ, Greenleaf JF, Manduca A, Ehman RL. Magnetic resonance elastography by direct visualization of propagating acoustic strain waves. Science. 1995; 269: 1854-7.

National Bioethics Advisory Commission. Research Involoving Human Biological Materials: Ethical Issues and Policy Guidance. Volume I, Report and Recommendations of the National Bioethics Advisory Commission. Rockville, MD; 1999.

National Institutes of Health. National Institutes of Health Consensus Conference on Breast Cancer Screening for Women Ages 40-49. J Natl Cancer Inst Monogr. 1997: 1-156. Proceedings. Bethesda, Maryland, USA.

National Research Council/ Board On Science Technology, and Economic Policy. The Small Business Innovation Research Program: Challenges and Opportunities. Washington, D.C.: National Academy Press; 1999.

Nayar R, Zhuang Z, Merino MJ, Silverberg SG. Loss of heterozygosity on chromosome 11q13 in lobular lesions of the breast using tissue microdissection and polymerase chain reaction. Hum Pathol. 1997; 28: 277-82.

Newman L. Larger debate underlies spiral CT screening for lung cancer [news]. J Natl Cancer Inst. 2000; 92: 592-4.

Page 262

Nichols KE, Levitz S, Shannon KE, et al. Heterozygous germline ATM mutations do not contribute to radiation-associated malignancies after Hodgkin's disease. J Clin Oncol. 1999; 17: 1259.

Nields MW, Galaty RR Jr. Digital mammography: a model for assessing cost-effectiveness. Acad Radiol. 1998 Sep; 5 Suppl 2: S310-3.

Nielsen M, Thomsen JL, Primdahl S, Dyreborg U, Andersen JA. Breast cancer and atypia among young and middle-aged women: a study of 110 medicolegal autopsies. Br J Cancer. 1987; 56: 814-9.

Niklason LT, Christian BT, Niklason LE, et al. Digital tomosynthesis in breast imaging. Radiology. 1997; 205: 399-406.

Nishikawa RM. Computer-aided diagnosis complements full-field digital mammography. Diagn Imaging (San Franc). 1999; 21: 47-51, 75.

Ntziachristos V, Yodh AG, Schnall M, Chance B. Concurrent MRI and diffuse optical tomography of breast after indocyanine green enhancement. Proc Natl Acad Sci U S A. 2000; 97: 2767-72.

Ophir J, Alam SK, Garra B, et al. Elastography: ultrasonic estimation and imaging of the elastic properties of tissues. Proc Inst Mech Eng [H]. 1999; 213: 203-33.

Osin P, Shipley J, Lu YJ, Crook T, Gusterson BA. Experimental pathology and breast cancer genetics: new technologies. Recent Results Cancer Res. 1998; 152: 35-48.

Osterman KS, Kerner TE, Williams DB, Hartov A, Poplack SP, Paulsen KD. Multifrequency electrical impedance imaging: preliminary in vivo experience in breast. Physiol Meas. 2000; 21: 99-109.

Page MJ, Amess B, Townsend RR, et al. Proteomic definition of normal human luminal and myoepithelial breast cells purified from reduction mammoplasties. Proc Natl Acad Sci U S A. 1999; 96: 12589-94.

Pantel K, Cote RJ, Fodstad O. Detection and clinical importance of micrometastatic disease. J Natl Cancer Inst. 1999; 91: 1113-24.

Papanicolaou GN, Holmquist DG, Bader GM, Falk EA. Exfoliative cytology of the human mammary gland and its value in the diagnosis of cancer and other diseases of the breast. Cancer (Phila.). 1958; 11: 377-409.

Parmigiani G, Berry D, Aguilar O. Determining carrier probabilities for breast cancer-susceptibility genes BRCA1 and BRCA2. Am J Hum Genet. 1998; 62: 145-58.

Perou CM, Jeffrey SS, van de Rijn M, et al. Distinctive gene expression patterns in human mammary epithelial cells and breast cancers. Proc Natl Acad Sci U S A. 1999; 96: 9212-7.

Perou CM, Sorlie T, Eisen MB, et al. Molecular portraits of human breast tumours. Nature. 2000; 406: 747-52.

Perry S, Thamer M. Medical innovation and the critical role of health technology assessment. JAMA. 1999; 282: 1869-72.

Petersen OW, Ronnov-Jessen L, Howlett AR, Bissell MJ. Interaction with basement membrane serves to rapidly distinguish growth and differentiation pattern of normal and malignant human breast epithelial cells [published erratum appears in Proc Natl Acad Sci U S A 1993 Mar 15; 90(6): 2556]. Proc Natl Acad Sci U S A. 1992; 89: 9064-8.

Peto R, Boreham J, Clarke M, Davies C, Beral V. UK and USA Breast Cancer Deaths Down 25% in Year 2000 at Ages 20-69 Years [Letter]; 2000. Lancet 355: 9217-1822.

Phelps ME. PET: the merging of biology and imaging into molecular imaging. J Nucl Med. 2000; 41: 661-81.

Phillips KA, Kerlikowske K, Baker LC, Chang SW, Brown ML. Factors associated with women's adherence to mammography screening guidelines. Health Serv Res. 1998; 33: 29-53.

Physicians Insurers Association of America. Breast Cancer Study. Rockville, MD: Physicians Insurers Association of America; 1995.

Page 263

Physicians Insurers Association of America. Practice Standards Claims Survey. Rockville, MD: Physicians Insurers Association of America; 1997.

Pisano ED, Earp J, Schell M, Vokaty K, Denham A. Screening behavior of women after a false-positive mammogram. Radiology. 1998a; 208: 245-9.

Pisano ED, Fajardo LL, Tsimikas J, et al. Rate of insufficient samples for fine-needle aspiration for nonpalpable breast lesions in a multicenter clinical trial: The Radiologic Diagnostic Oncology Group 5 Study. The RDOG5 investigators. Cancer. 1998b; 82: 679-88.

Pisano ED, Parham CA. Digital mammography, sestamibi breast scintigraphy, and positron emission tomography breast imaging. Radiol Clin North Am. 2000; 38: 861-9, x.

Pisano ED, Yaffe MJ, Hemminger BM, et al. Current status of full-field digital mammography. Acad Radiol. 2000; 7: 266-80.

Plevritis, SK. A framework for evaluating the cost-effectiveness of MRI screening for breast cancer. Eur. Radiology. 2000a; 10 Suppl. 3: 5430-2.

Plevritis SK. Simulation of breast cancer screening trials. Outcomes and Cost-effectiveness (Methology Development). Lucas Annual 2000. 2000b. Stanford, CA.

Plewes DB, Bishop J, Samani A, Sciarretta J. Visualization and quantification of breast cancer biomechanical properties with magnetic resonance elastography. Phys Med Biol. 2000; 45: 1591-610.

Pollack JR, Perou CM, Alizadeh AA, et al. Genome-wide analysis of DNA copy-number changes using cDNA microarrays. Nat Genet. 1999; 23: 41-6.

Pollak MN. Endocrine effects of IGF-I on normal and transformed breast epithelial cells: potential relevance to strategies for breast cancer treatment and prevention. Breast Cancer Res Treat. 1998; 47: 209-17.

Potosky AL, Breen N, Graubard BI, Parsons PE. The association between health care coverage and the use of cancer screening tests. Results from the 1992 National Health Interview Survey [published erratum appears in Med Care 1998 Oct; 36(10): 1470]. Med Care. 1998; 36: 257-70.

PricewaterhouseCoopers Money Tree ^™ Survey, www.pwcmoneytree.com (accessed August 2000 and March 2001).

Prorok PC, Kramer BS, Gohagan JK. Screening theory and study design: the basics. From: Kramer BS, Gohagan JK, Prorok PC, eds. Cancer Screening: Theory and Practice. New York: M. Dekker; 1999: 29-53.

Rao PN, Levine E, Myers MO, et al. Elevation of serum riboflavin carrier protein in breast cancer. Cancer Epidemiol Biomarkers Prev. 1999; 8: 985-90.

Rathore SS, McGreevey JD 3rd, Schulman KA, Atkins D. Mandated coverage for cancer-screening services: whose guidelines do states follow? Am J Prev Med. 2000; 19: 71-8.

Rettig RA. Health Care in Transition: Technology Assessment in the Private Sector. Santa Monica, CA: RAND; 1997.

Reynolds T. Gene patent race speeds ahead amid controversy, concern. J Natl Cancer Inst. 2000; 92: 184-6.

Ries LAG, Kosary CL, Hankey BFeale. SEER Cancer Statistic Review, 1973-1996. Bethesda, MD; 1999.

Rimer BK, Keintz MK, Kessler HB, Engstrom PF, Rosan JR. Why women resist screening mammography: patient-related barriers. Radiology. 1989; 172: 243-6.

Rodenko GN, Harms SE, Pruneda JM, et al. MR imaging in the management before surgery of lobular carcinoma of the breast: correlation with pathology. Am J Roentgenol. 1996; 167: 1415-9.

Roebuck JR, Cecil KM, Schnall MD, Lenkinski RE. Human breast lesions: characterization with proton MR spectroscopy. Radiology. 1998; 209: 269-75.

Rosen PP. Clinical implications of preinvasive and small invasive breast carcinomas. Pathol Annu. 1981; 16: 337-56.

Page 264

Rosen PP, Braun DW Jr, Kinne DE. The clinical significance of pre-invasive breast carcinoma. Cancer. 1980; 46: 919-25.

Rosencwaig A. Photoacoustic spectroscopy. Anal Chem. 1975; 47: 592-602.

Rosenquist CJ, Lindfors KK. Screening mammography beginning at age 40 years: a reappraisal of cost-effectiveness. Cancer. 1998; 82: 2235-40.

Rothenberg K, Fuller B, Rothstein M, et al. Genetic information and the workplace: legislative approaches and policy changes. Science. 1997; 275: 1755-7.

Rubin M, Horiuchi K, Joy N, et al. Use of fine needle aspiration for solid breast lesions is accurate and cost-effective. Am J Surg. 1997; 174: 694-6; discussion 697-8.

Russo IH, Russo J. Mammary gland neoplasia in long-term rodent studies. Environ Health Perspect. 1996; 104: 938-67.

Russo J, Russo IHNMC, Daniel CWe. Development of human mammary gland. The Mammary Gland. 1987: 67-105. Plenum: New York.

Sapirstein W. The conduct of clinical trials: a Food and Drug Agency perspective. ASAIO J. 2000; 46: 29-30.

Sauter ER, Ehya H, Babb J, et al. Biological markers of risk in nipple aspirate fluid are associated with residual cancer and tumour size. Br J Cancer. 1999; 81: 1222-7.

Sauter ER, Ross E, Daly M, et al. Nipple aspirate fluid: a promising non-invasive method to identify cellular markers of breast cancer risk. Br J Cancer. 1997; 76: 494-501.

Schubert EL, Lee MK, Newman B, King MC. Single nucleotide polymorphisms (SNPs) in the estrogen receptor gene and breast cancer susceptibility. J Steroid Biochem Mol Biol. 1999; 71: 21-7.

Scopinaro F, Pani R, De Vincentis G, Soluri A, Pellegrini R, Porfiri LM. High-resolution scintimammography improves the accuracy of technetium-99m methoxyisobutylisonitrile scintimammography: use of a new dedicated gamma camera. Eur J Nucl Med. 1999; 26: 1279-88.

Scott S, Morrow M. Breast cancer. Making the diagnosis. Surg Clin North Am. 1999; 79: 991-1005.

Semiglazov VF, Moiseenko VM, Manikhas AG, et al. Interim results of a prospective randomized study of self-examination for early detection of breast cancer ( Russia/St. Petersburg/WHO). Vopr Onkol. 1999; 45: 265-71.

Semiglazov VF, Moiseyenko VM, Bavli JL, et al. The role of breast self-examination in early breast cancer detection (results of the 5-years USSR/WHO randomized study in Leningrad). Eur J Epidemiol. 1992; 8: 498-502.

Service RF. Biochemistry. Protein arrays step out of DNA's shadow. Science. 2000; 289: 1673.

Shafman TD, Levitz S, Nixon AJ, et al. Prevalence of germline truncating mutations in ATM in women with a second breast cancer after radiation therapy for a contralateral tumor. Genes Chromosomes Cancer. 2000; 27: 124-9.

Shalala D. “Report of the Secretary to the President: Health insurance in the age of genetics.” ( July 1997).

Shapiro S. Periodic screening for breast cancer: the HIP Randomized Controlled Trial. Health Insurance Plan. J Natl Cancer Inst Monogr. 1997: 27-30.

Sharan SK, Morimatsu M, Albrecht U, et al. Embryonic lethality and radiation hypersensitivity mediated by Rad51 in mice lacking BRCA2. Nature. 1997; 386: 804-10.

Shayeghi M, Seal S, Regan J, et al. Heterozygosity for mutations in the ataxia telangiectasia gene is not a major cause of radiotherapy complications in breast cancer patients. Br J Cancer. 1998; 78: 922-7.

Sidransky D, Tokino T, Helzlsouer K, et al. Inherited p53 gene mutations in breast cancer. Cancer Res. 1992; 52: 2984-6.

Siegel JE, Weinstein MC, Russell LB, Gold MR. Recommendations for reporting cost-effectiveness analyses. Panel on Cost-Effectiveness in Health and Medicine. JAMA. 1996; 276: 1339-41.

Page 265

Silverstein MJ, Lagios MD. Use of predictors of recurrence to plan therapy for DCIS of the breast. Oncology (Huntingt). 1997; 11: 393-406, 409-10; discussion 413-5.

Sinkus R, Lorenzen J, Schrader D, Lorenzen M, Dargatz M, Holz D. High-resolution tensor MR elastography for breast tumour detection. Phys Med Biol. 2000; 45: 1649-64.

Sirovich BE, Sox HC Jr. Breast cancer screening. Surg Clin North Am. 1999; 79: 961-90.

Skoumal SM, Florell SR, Bydalek MK, Hunter WJ 3rd. Malpractice protection: communication of diagnostic uncertainty. Diagn Cytopathol. 1996; 14: 385-9.

Smith-Bindman R, Kerlikowske K, Gebretsadik T, Newman J. Is screening mammography effective in elderly women? Am J Med. 2000; 108: 112-9.

Smith HS, Lan S, Ceriani R, Hackett AJ, Stampfer MR. Clonal proliferation of cultured nonmalignant and malignant human breast epithelia. Cancer Res. 1981; 41: 4637-43.

Smith R.A. Risk-Based Screening For Breast Cancer: Is There a Practical Strategy? Seminars in Breast Disease. 1999; 2: 280-91.

Sneige N. A comparison of fine needle aspiration, core biopsy, and needle localization biopsy techniques in mammographically detectable nonpalpable breast lesions. Pathol Case Rev. 1991; 1.

Softcheck J.T. President Clinton signs bill to create NIH Institute of Biomedical Imaging and Bioengineering: NIH effort to build Office of Bioengineering, Bioimaging and Bioinformatics effectively derailed. Washington Fax. 2001.

Stavros AT, Thickman D, Rapp CL, Dennis MA, Parker SH, Sisney GA. Solid breast nodules: use of sonography to distinguish between benign and malignant lesions. Radiology. 1995; 196: 123-34.

Straus E. Magnetic resonance imaging. Detecting enzyme activity in live animals [news]. Science. 2000; 287: 1575.

Strongin R. Medicare coverage and technology diffusion: past, present, and future. Issue Brief Natl Health Policy Forum. 1998: 1-8.

Struewing JP, Hartge P, Wacholder S, et al. The risk of cancer associated with specific mutations of BRCA1 and BRCA2 among Ashkenazi Jews. N Engl J Med. 1997; 336: 1401-8.

Stuntz ME, Khalkhali I, Kakuda JT, Klein SR, Vargas HI. Scintimammography. Seminars In Breast Disease. 1999; 2: 97-106.

Suleiman OH, Spelic DC, McCrohan JL, Symonds GR, Houn F. Mammography in the 1990s: the United States and Canada. Radiology. 1999; 210: 345-51.

Swift M, Morrell D, Massey RB, Chase CL. Incidence of cancer in 161 families affected by ataxia-telangiectasia. N Engl J Med. 1991; 325: 1831-6.

Tabar L, Dean PB, Kaufman CS, Duffy SW, Chen HH. A new era in the diagnosis of breast cancer. Surg Oncol Clin N Am. 2000; 9: 233-77.

Tabar L, Duffy SW, Vitak B, Chen HH, Prevost TC. The natural history of breast carcinoma: what have we learned from screening? Cancer. 1999; 86: 449-62.

Tan JE, Orel SG, Schnall MD, Schultz DJ, Solin LJ. Role of magnetic resonance imaging and magnetic resonance imaging—guided surgery in the evaluation of patients with early-stage breast cancer for breast conservation treatment. Am J Clin Oncol. 1999; 22: 414-8.

Tavtigian SV, Simard J, Rommens J, et al. The complete BRCA2 gene and mutations in chromosome 13q-linked kindreds. Nat Genet. 1996; 12: 333-7.

Taylor-Papadimitriou J, Stampfer MR ( Freshney RI, Editor); Culture of Human Mammary Epithelial Cells. Culture of Epithelial Cells. Wiley-Liss, USA; 1992: 107-33.

The Lewin Group/AdvaMed. Outlook For Medical Technology Innovation. Will Patients Get The Care They Need? 1999; 1.

The Lewin Group/AdvaMed. Outlook For Medical Technology Innovation. Will Patients Get The Care They Need? 2000; 2.

Thomas DB, Gao DL, Self SG, et al. Randomized trial of breast self-examination in Shanghai: methodology and preliminary results. J Natl Cancer Inst. 1997; 89: 355-65.

Page 266

Thomsen S, Tatman D. Physiological and pathological factors of human breast disease that can influence optical diagnosis. Ann N Y Acad Sci 1998 Feb 9; 838: 171-93.

Thurfjell EL, Lernevall KA, Taube AA. Benefit of independent double reading in a population-based mammography screening program. Radiology. 1994; 191: 241-4.

Thurfjell E, Thurfjell MG, Egge E, Bjurstam N. Sensitivity and specificity of computer-assisted breast cancer detection in mammography screening. Acta Radiol. 1998; 39: 384-8.

Tonetti DA, Jordan VC. The role of estrogen receptor mutations in tamoxifen-stimulated breast cancer. J Steroid Biochem Mol Biol. 1997; 62: 119-28.

U.S. Congress, Office of Technology Assessment. “Identifying Health Technologies that Work: Searching for Evidence.” OTA-H-608 ( Washington, D.C., U.S. Government Printing Office, September, 1994).

U.S. Department of Health and Human Services. Health, United States, 2000. With Adolescent Health Chartbook: Department of Health and Human Services; 2000.

U.S. General Accounting Office. Mammography Quality Standards Act: X-Ray Quality Improved, Access Unaffected, but Impact on Health Outcomes Unknown; 1998a. GAO/HEHS98-164.

U.S. General Accounting Office. Mammography Services: Impact of Federal Legislation on Quality, Access, and Health Outcomes; 1998b. GAO/HEHS-98-11.

U.S. Preventive Services Task Force, Screening for breast cancer. In:. Guide to Clinical Preventive Services. 2nd ed. Baltimore MD: Williams & Wilkins; 1996: 73-88. HealthSTAR.

Van Dijck JA, Verbeek AL, Beex LVHJH, et al. Mammographic screening after the age of 65 years: evidence for a reduction in breast cancer mortality. Int J Cancer. 1996; 66: 727-31.

van Dijck JA, Verbeek AL, Hendriks JH, Holland R. The current detectability of breast cancer in a mammographic screening program. A review of the previous mammograms of interval and screen-detected cancers. Cancer. 1993; 72: 1933-8.

Velanovich V, Lewis FR Jr, Nathanson SD, et al. Comparison of mammographically guided breast biopsy techniques. Ann Surg. 1999; 229: 625-30; discussion 630-3.

Vernon SW, Laville EA, Jackson GL. Participation in breast screening programs: a review. Soc Sci Med. 1990; 30: 1107-18.

Vetto JT, Pommier RF, Schmidt WA, Eppich H, Alexander PW. Diagnosis of palpable breast lesions in younger women by the modified triple test is accurate and cost-effective. Arch Surg. 1996; 131: 967-72; discussion 972-4.

Wagner SK. Verdict on MQSA: quality up, but so is financial burden. Diagn Imaging (San Franc). 1999; 21: 33-4, 62.

Warren-Burhenne LJ, Wood SA, D'Orsi CJ, et al. Potential contribution of computer-aided detection to the sensitivity of screening mammography [published erratum appears in Radiology 2000 Jul; 216(1): 306]. Radiology. 2000; 215: 554-62.

Webber RL, Horton RA, Tyndall DA, Ludlow JB. Tuned-aperture computed tomography (TACT). Theory and application for three-dimensional dento-alveolar imaging. Dentomaxillofac Radiol. 1997; 26: 53-62.

Weidner N. Prognostic factors in breast carcinoma. Curr Opin Obstet Gynecol. 1995; 7: 4-9.

Weidner N, Folkman J, Pozza F, et al. Tumor angiogenesis: a new significant and independent prognostic indicator in early-stage breast carcinoma. J Natl Cancer Inst. 1992; 84: 1875-87.

Welch HG, Black WC. Using autopsy series to estimate the disease “reservoir” for ductal carcinoma in situ of the breast: how much more breast cancer can we find? Ann Intern Med. 1997; 127: 1023-8.

Welcsh PL, Owens KN, King MC. Insights into the functions of BRCA1 and BRCA2. Trends Genet. 2000; 16: 69-74.

Page 267

Welsch CW, Medina D, Kidwell W, Heppner G, Anderson E. Rodent models to examine in vivo hormonal regulation of mammary gland tumorigenesis. Cellular and Molecular Biology of Mammary Cancer. 1987: 163-79.

Wen H. Volumetric Hall effect tomography—a feasibility study. Ultrason Imaging. 1999; 21: 186-200.

Wen H, Shah J, Balaban RS. Hall effect imaging. IEEE Trans Biomed Eng. 1998; 45: 119-24.

White E, Velentgas P, Mandelson MT, et al. Variation in mammographic breast density by time in menstrual cycle among women aged 40-49 years. J Natl Cancer Inst. 1998; 90: 906-10.

Wilson JMG, Jungren G. Principles and practice of screening for disease. Public Health Paper (No. 34). Geneva, World Health Organization. 1968; 26.

Wismar BA (Kramer EJ, Ivey SL, Ying Y-W, Editors); Breast and Cervical Cancer. Immigrant Women's Health, Problems and Solutions. San Francisco, CA: Jossey-Bass Publishers; 1999.

Wong AY, Salisbury E, Bilous M. Recent developments in stereotactic breast biopsy methodologies: an update for the surgical pathologist. Adv Anat Pathol. 2000; 7: 26-35.

Wooster R, Bignell G, Lancaster J, et al. Identification of the breast cancer susceptibility gene BRCA2 [published erratum appears in Nature 1996 Feb 22; 379(6567): 749]. Nature. 1995; 378: 789-92.

Wrensch MR, Petrakis NL, King EB, et al. Breast cancer incidence in women with abnormal cytology in nipple aspirates of breast fluid. Am J Epidemiol. 1992; 135: 130-41.

Wun LM, Merrill RM, Feuer EJ. Estimating lifetime and age-conditional probabilities of developing cancer. Lifetime Data Anal. 1998; 4: 169-86.

Yabroff KR, Mandelblatt JS. Interventions targeted toward patients to increase mammography use. Cancer Epidemiol Biomarkers Prev. 1999; 8: 749-57.

Yan H, Kinzler KW, Vogelstein B. Tech.sight. Genetic testing—present and future. Science. 2000; 289: 1890-2.

Yan PS, Perry MR, Laux DE, Asare AL, Caldwell CW, Huang TH. CpG island arrays: an application toward deciphering epigenetic signatures of breast cancer. Clin Cancer Res. 2000; 6: 1432-8.

Ziewacz JT, Neumann DP, Weiner RE. The difficult breast. Surg Oncol Clin N Am. 1999; 8: 17-33.

Page 268